Dyne Therapeutics, Inc. (NasdaqGS: DYN)
Health Care · Biotechnology · US
$26.34
+1.35% today · +102.6% 1Y
Dyne Therapeutics, Inc. (NasdaqGS: DYN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.92B and employs 289 people.
Over the last twelve months the share price has gained 102.6%, trading between 11.92 and 27.31.
Tweenvest scores Dyne Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
DYN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.92B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.35
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $27.31
- 52-week low
- $11.92
- Avg volume (3M)
- —
- Shares outstanding
- 186.75M
- Employees
- 289
- Next earnings
- —
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
- ISIN
- US26818M1080
- Founded
- 2017
- Listed since
- Sep 17, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $153.70 | -3.23% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.